Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Female Orgasmic Difficulty topic
No spam. Unsubscribe anytime.
Board adds female orgasmic difficulty as an adult qualifying condition after petitioner’s presentation and research summary
Summary
The board voted to add female orgasmic difficulty as a debilitating condition for adults only after a public petitioner summarized historical and recent studies and testified that cannabis improved outcomes for many women.
The Connecticut Medical Marijuana Program Board of Physicians voted to add female orgasmic difficulty (FOD) to the program’s list of qualifying debilitating conditions for adults.
Suzanne Mulvihill Hill, who identified herself as executive director of a nonprofit (the Female ****** Research Institute) and director of the Women’s Cannabis Project, presented research and her dissertation work on cannabis as a treatment for female orgasmic difficulty. She told the board that historical and recent studies — including observational analyses — report associations between cannabis use and improved sexual function, and described mixed-methods research she conducted that found statistically significant improvement in frequency, ease and satisfaction measures when women used cannabis.
“Up to 41 percent of women suffer from it,” Mulvihill Hill said in summarizing prevalence estimates from past literature, and she described case-level reports and survey findings in which women reported clinically meaningful benefit when using low, titrated doses of CBD/THC products prior to partnered sex or on a regular basis.
Board members questioned dosing, pediatric applicability, and clinical pathways. Members and the petitioner agreed that the petition applied only to adults; the board recorded that the question of under-18 patients was not before it. A motion to approve the petition for adults was moved and seconded and carried by voice vote; members indicated “aye.” The board recorded that marijuana is more likely than not to have potential benefit to alleviate debilitation associated with the condition, and that the condition meets the regulatory definition of debilitating.
The board discussed how clinicians unfamiliar with FOD might identify patients and agreed the practical pathway would likely involve behavioral health or sexual-health clinicians working with physicians who can certify patients under program rules. Staff said paperwork to finalize the adult-only approval would be circulated after the meeting.
The board did not extend the approval to pediatric patients; any future petition for under-18 treatment would require separate consideration and evidence.
